NFKB1 and colitis: In this research, we revealed that the application of GMEVs could reduce the secretion of pro-inflammatory cytokines and increase the expression of anti-inflammatory cytokines by inhibiting IκBα and NF-κB p65 phosphorylation in the NF-κB signaling pathway, improving the symptoms of DSS-induced colitis.